In a landmark decision, a High Court judge has ruled that the temporary ban on prescribing puberty blockers to children with gender dysphoria in England, Scotland, and Wales is lawful.
This ruling comes after the Conservative government’s emergency order, issued on May 29, which temporarily prohibited the supply of puberty blockers based on overseas prescriptions.
The decision followed a critical review by Dr. Hilary Cass into gender medicine.
The Cass review raised significant concerns about the lack of evidence regarding the benefits and risks associated with puberty blockers.
Consequently, the legislation was introduced to ensure that these medications could only be accessed through authorized clinical trials.
TransActual, an advocacy group, and a young person whose identity remains confidential, contested the ban. They argued that the emergency order lacked thoroughness and was influenced by the personal beliefs of then-health secretary, Victoria Atkins.
The challengers claimed Atkins had failed to identify the “serious danger to health” necessary to justify such emergency legislation and criticized the lack of prior consultation before the order was enacted.
Court Supports Ban Based on Risks
However, Mrs. Justice Lang in a judgment delivered on Monday, July 29 upheld the legality of Atkins’ actions.
“It was rational for the first defendant to decide that it was essential to adopt the emergency procedure to avoid serious danger to the health of children and young people who would otherwise be prescribed puberty blockers during that five- to six-month period. Under the emergency procedure, there is no requirement to hold a consultation procedure.”
Mrs. Justice Lang
Justice Lang also emphasized the findings of the Cass review.
“The Cass review’s findings about the very substantial risks and very narrow benefits associated with the use of puberty blockers, and the recommendation that in future the NHS prescribing of puberty blockers to children and young people should only take place in a clinical trial, and not routinely, amounted to powerful scientific evidence in support of restrictions on the supply of puberty blockers on the grounds that they were potentially harmful.”
Mrs. Justice Lang
While the review did not explicitly conclude that puberty blockers posed a serious health danger, Lang pointed out that this was not the question the review aimed to address.
She also highlighted that the implementation of the review’s findings by NHS England, the Royal College of GPs, and the General Pharmaceutical Council lent further credibility to the restrictions.
During last month’s hearing, the court heard testimonies regarding the impact of the temporary ban on over 1,000 under-18s.
Lang acknowledged, “The claimants’ evidence does show that this cohort has had difficulties in obtaining access to UK-registered GPs and mental health services since the order was made.”
She suggested that the primary issue was not the legality of the order but rather the effectiveness of its implementation.
“NHS England and the DHSC [Department for Health and Social Care] should consider how implementation can be improved as soon as possible, and in any event, before the next order is made,” Lang added.
Health Secretary Wes Streeting, who is reportedly considering making the ban permanent, responded to the High Court’s ruling by stressing the importance of evidence-based healthcare for children.
“Dr. Cass’s review found there was insufficient evidence that puberty blockers are safe and effective for children with gender dysphoria and gender incongruence. We must therefore act cautiously and with care when it comes to this vulnerable group of young people.”
Wes Streeting
The High Court’s decision marks a significant moment in the ongoing debate over the use of puberty blockers in the treatment of gender dysphoria in minors, reflecting the complexities and challenges of balancing medical caution with the needs of vulnerable young people.
READ ALSO: Security Services Recruitment: Minority Petitions CHRAJ Over Alleged Unfair Recruitment Practices
